Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.
Everolimus (Certican; Novartis Pharma AG, Basel, Switzerland) represents the latest generation of proliferation signal inhibitors (PSIs). Everolimus is indicated for use as an immunosuppressive drug in renal and heart transplantation. This report reflects the recommendations of the second German-Austrian Certican Consensus Conference, held in January 2006, for the clinical use of everolimus.
Rothenburger
Markus
M
Department of Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, Germany. markus.rothenburger@novartis.com
Zuckermann
Andreas
A
Bara
Christoph
C
Hummel
Manfred
M
Strüber
Martin
M
Hirt
Stephan
S
Lehmkuhl
Hans
H
D000799:Angioedema / Q000139:chemically induced; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control; D004347:Drug Interactions; D016903:Drug Monitoring; D000068338:Everolimus; D006331:Heart Diseases / Q000150:complications / Q000601:surgery; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D051437:Renal Insufficiency / Q000150:complications; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012871:Skin Diseases / Q000139:chemically induced; D014184:Transplantation, Homologous; D014945:Wound Healing / Q000187:drug effects
D007166:Immunosuppressive Agents; D008055:Lipids; D000068338:Everolimus; D020123:Sirolimus